新辅助化疗联合靶向治疗对老年胃癌患者的临床应用分析(1)
[摘要] 目的 分析探究新輔助化疗联合靶向治疗对老年胃癌患者的临床应用。 方法 方便选取2018年11月—2019年11月该院收治的老年Her-2过表达胃上部癌症患者98例为研究对象，采用电脑随机分组法将其分为对照组与实验组，每组49例，对照组患者除了口服卡培他滨以外，还需要静脉滴注奥沙利铂进行治疗，实验组在此基础上添加赫赛汀静脉滴注。对比两组患者临床治疗效果、生存时间以及不良反应发生率。 结果 对照组患者临床治疗控制率为85.71%，总有效率为67.35%;实验组患者临床治疗控制率为97.96%(χ2=4.900，P=0.027)，总有效率为93.88%(χ2=11.033，P=0.016)，实验组临床治疗效果显著高于对照组临床治疗效果;实验组患者与实验组患者不良反应对比均差异无统计学意义(P>0.05);两组患者治疗1年后，通过电话回访发现，实验组患者存活率为95.92%，对照组患者存活率为73.47%(χ2=9.243，P=0.021)，实验组患者存活率显著高于对照组。结论 新辅助化疗联合靶向治疗对老年胃癌患者的临床应用效果良好，有效延长患者生存时间，值得临床推广应用。
[关键词] 新辅助化疗;靶向治疗;老年胃癌;临床应用
[中图分类号] R735.2 [文献标识码] A [文章编号] 1674-0742(2020)09(c)-0090-04
[Abstract] Objective To analyze and explore the clinical application of neoadjuvant chemotherapy combined with targeted therapy in elderly patients with gastric cancer. Methods A total of 98 elderly patients with Her-2 overexpression gastric cancer who were admitted to the hospital from November 2018 to November 2019 were convenient selected as the research objects. The computer randomized grouping method was used to divide them into a control group and an experimental group， each with 49 cases， the control group needed intravenous infusion of oxaliplatin in addition to oral capecitabine， and the experimental group added Herceptin intravenously on this basis. The clinical treatment effect， survival time and incidence of adverse reactions were compared between the two groups. Results The clinical treatment control rate of patients in the control group was 85.71%， and the total effective rate was 67.35%; the clinical treatment control rate of patients in the experimental group was 97.96% (χ2=4.900， P=0.027)， and the total effective rate was 93.88%(χ2=11.033， P=0.016)， the clinical treatment effect of the experimental group was significantly higher than that of the control group; there was no statistically significant difference in adverse reactions between the observation group and the experimental group(P>0.05); the two groups of patients were treated for 1 year， through the telephone return visit， the survival rate of patients in the experimental group was 95.92%， the survival rate of patients in the control group was 73.47% (χ2=9.243， P=0.021)， and the survival rate of patients in the experimental group was significantly higher than that of the control group. Conclusion Neoadjuvant chemotherapy combined with targeted therapy has a good clinical application effect on elderly patients with gastric cancer， effectively prolonging the survival time of patients， and it is worthy of clinical application., http://www.100md.com(孙莹)
[关键词] 新辅助化疗;靶向治疗;老年胃癌;临床应用
[中图分类号] R735.2 [文献标识码] A [文章编号] 1674-0742(2020)09(c)-0090-04
[Abstract] Objective To analyze and explore the clinical application of neoadjuvant chemotherapy combined with targeted therapy in elderly patients with gastric cancer. Methods A total of 98 elderly patients with Her-2 overexpression gastric cancer who were admitted to the hospital from November 2018 to November 2019 were convenient selected as the research objects. The computer randomized grouping method was used to divide them into a control group and an experimental group， each with 49 cases， the control group needed intravenous infusion of oxaliplatin in addition to oral capecitabine， and the experimental group added Herceptin intravenously on this basis. The clinical treatment effect， survival time and incidence of adverse reactions were compared between the two groups. Results The clinical treatment control rate of patients in the control group was 85.71%， and the total effective rate was 67.35%; the clinical treatment control rate of patients in the experimental group was 97.96% (χ2=4.900， P=0.027)， and the total effective rate was 93.88%(χ2=11.033， P=0.016)， the clinical treatment effect of the experimental group was significantly higher than that of the control group; there was no statistically significant difference in adverse reactions between the observation group and the experimental group(P>0.05); the two groups of patients were treated for 1 year， through the telephone return visit， the survival rate of patients in the experimental group was 95.92%， the survival rate of patients in the control group was 73.47% (χ2=9.243， P=0.021)， and the survival rate of patients in the experimental group was significantly higher than that of the control group. Conclusion Neoadjuvant chemotherapy combined with targeted therapy has a good clinical application effect on elderly patients with gastric cancer， effectively prolonging the survival time of patients， and it is worthy of clinical application., http://www.100md.com(孙莹)